Mesoblast has ignited a high-margin commercial engine with first-ever FDA-approved MSC therapy—now the upside hinges on adult GvHD expansion and blockbuster pipeline execution.
Overview
Mesoblast (ASX:MSB; Nasdaq:MESO) is transitioning from a long-duration clinical-stage biotech into a commercial-stage regenerative medicine company following the successful U.S. launch of Ryoncil, the first FDA-approved mesenchymal stromal cell therapy for any indication. The current revenue engine is direct U.S. sales of Ryoncil for pediatric steroid-refractory acute GvHD, a high-acuity orphan setting served through a concentrated set of transplant centers. The model features exceptional economics (US$194k WAC per infusion; ~93% gross margin) and is supported by reimbursement infrastructure (permanent J-code) and cold-chain logistics. Beyond Ryoncil, the investment case depends on adult GvHD expansion and late-stage pipeline optionality in CLBP and heart failure via the more potent MPC platform (Revascor), with additional upside from CAR-enhanced MSC technology.